Clinical Trials Directory

Trials / Completed

CompletedNCT05621447

A Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
6 (actual)
Sponsor
Taiho Pharmaceutical Co., Ltd. · Industry
Sex
Male
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

To evaluate the pharmacokinetics, mass balance recovery, metabolite profile and metabolite identification of \[14C\]TAS-303 following oral single dose

Conditions

Interventions

TypeNameDescription
DRUGTAS-303, [14C]TAS-303oral administration on day 1

Timeline

Start date
2022-09-07
Primary completion
2022-11-03
Completion
2023-02-22
First posted
2022-11-18
Last updated
2023-08-07

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT05621447. Inclusion in this directory is not an endorsement.